Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 11/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12990958 | 0.87 | OPRL1 (0.47) | OPRL1OPRM1OPRK1OPRD1SIGMAR1 | |
| SCHEMBL12991013 | 0.86 | OPRL1 (0.40) | OPRL1OPRM1 | |
| SCHEMBL12991021 | 0.86 | OPRL1 (0.40) | OPRL1OPRM1 | |
| SCHEMBL12990965 | 0.85 | OPRL1 (0.39) | OPRL1OPRM1 | |
| SCHEMBL12991123 | 0.82 | OPRL1 (0.50) | OPRL1OPRM1OPRK1OPRD1SIGMAR1 | |
| SCHEMBL12991356 | 0.81 | DRD2 (0.33) | DRD2 | |
| SCHEMBL12991132 | 0.81 | HTR4 (0.37) | DRD2 | |
| SCHEMBL12991333 | 0.81 | KDM4E (0.36) | — | |
| SCHEMBL12990817 | 0.81 | KDM4E (0.36) | — | |
| SCHEMBL12991081 | 0.81 | CCR2 (0.36) | OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858790-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858790-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858790-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-28 | — | — | US | disclosed |
| US-20080033002-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2008-02-07 | — | — | US | disclosed |
| US-20080033002-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2008-02-07 | — | — | US | disclosed |
| US-20080033002-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2008-02-07 | — | — | US | disclosed |
| WO-2008005295-A2 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033002-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | OPRL1 69/4885OPRM1 66/4885OPRK1 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.